10 Years From Now

Eikon Tx: thoughts on the IPO of a techbio giant

World-class team, stellar science and a platform still searching for target classes where mechanistic clarity actually compounds into clinical advantage

Jan 30 • Abhijeet Patra

5

March 2025

Every idea is brilliant - until real-world-evidence says it is not

Let’s continue the discussion about drug-device/delivery products.

Mar 29, 2025 • Abhijeet Patra

1

Can you build a venture scale biotech company without making your own drugs?

Specifically, I am talking about companies building drug-device combinations or delivery mechanisms.

Mar 23, 2025 • Abhijeet Patra

3

February 2025

Cerebras shouldn't go public.

TLDR: that’s it.

Feb 18, 2025 • Abhijeet Patra

10

14

1

August 2021

Hardtech is becoming (somewhat) easier — Part 2

The role of precision manufacturing

Aug 20, 2021 • Abhijeet Patra

3

June 2021

Hardtech is becoming (somewhat) easier: the role of simulations

Advances in simulations are reducing the cost of every iteration and therefore, eventual risk

Jun 11, 2021 • Abhijeet Patra

3

May 2021

The hard thing about investing in hardtech

The decision to invest in hardtech boils down to understanding the risk profile associated with every individual venture. In absence of enough data…

May 11, 2021 • Abhijeet Patra

2

April 2021

What is hardtech and what is different about building it?

In the previous post, I talked about how frontier technology moves slowly at first and then over time, becomes indistinguishable from magic.

Apr 4, 2021 • Abhijeet Patra

6

March 2021

Issue #1: Frontier Technology is Magic

The technologies that our lives will revolve around in 10 years are being developed today. Far away from clickbait, slowly and in relative obscurity…

Mar 12, 2021 • Abhijeet Patra

10

2

A newsletter about the future and people who are building it

Welcome to 10 Years From Now by Abhijeet Patra.

Mar 12, 2021 • Abhijeet Patra

1